# A Study of Guselkumab Given After Ustekinumab in Participants With Moderate to Severe Psoriasis in Routine Clinical Practice

> **NCT07746583** · — · RECRUITING · sponsor: **Janssen-Cilag Kft.** · enrollment: 100 (estimated)

## Conditions studied

- Psoriasis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07746583
- **Lead sponsor:** Janssen-Cilag Kft.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-03
- **Primary completion:** 2029-01-30
- **Final completion:** 2029-03-15
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07746583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07746583, "A Study of Guselkumab Given After Ustekinumab in Participants With Moderate to Severe Psoriasis in Routine Clinical Practice". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07746583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*